Disc Medicine (IRON) Stock Analysis & Winston Score
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (0/30)
- Growth: Weak (1/20)
- Cash Flow: Data not available (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $76.15
Market Cap: $2.9B
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

